Lab21 is expanding its clinical diagnostics portfolio with the introduction of a new service to identify the two most common causes of fungal pneumonia. The CE-marked FXGTM:RESP (ASP+) test, developed by UK diagnostics company Myconostica, will identify infections caused by Aspergillus and Pneumocystis, which account for over 95% of cases of fungal pneumonia and could radically alter the diagnosis of fungal disease.
Verulam Scientific Ltd is an analytical instrument company providing innovative solutions and emerging technologies to the UK pharmaceutical, environmental, life science, food, clinical and biotechnology markets. We provide laboratories with the equipment and services that are crucial to modern analytical services and research.
Hyatt Regency, Vancouver, Canada
19-23 November, 2024
Hilton London Metropole, 255 Edgware Road, London, W2 1JU
11-12 December, 2024
Liverpool Arena and Convention Centre
31 March - 3 April, 2025
RAF Museum, Hendon, London NW9 5LL
15 May, 2025
ICC Ghent, Belgium
24-26 June, 2025
